Stocks News

Sartorius Stedim Biotech S.A. (SDMHF) Q4 2023 Earnings Call Transcript

Sartorius Stedim Biotech S.A. (OTCPK:SDMHF) Q4 2023 Earnings Call Transcript January 26, 2024 7:00 AM ET

Company Participants

Dr. Joachim Kreuzburg – IR

Rene Faber – Head of Bioprocess Solutions Division & Member

Conference Call Participants

Vineet Agrawal – Citi

Matthew Weston – UBS

Oliver Reinberg – Kepler Cheuvreux

Charles Pitman – Barclays

Richard Vosser – JPMorgan

Thibault Boutherin – Morgan Stanley

Odysseas Manesiotis – Berenberg

James Vane-Tempest – Jefferies.

Naresh Chouhan – Intron Health Research

Falko Friedrichs – Deutsche Bank

Oliver Metzger – ODDO

Sezgi Ozener – HSBC

Virendra Chauhan – AlphaValue

Markus Schmitt – ODDO

Operator

Ladies and gentlemen, welcome to the Sartorius and Sartorius Stedim Biotech conference call and live webcast on the preliminary full year 2023 results. I’m Sascha, the Chorus Call operator. (Operator Instructions) And the conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.

At this time, it is my pleasure to hand over to Dr. Joachim Kreuzburg. Please go ahead.

Dr. Joachim Kreuzburg

Thank you very much, and also welcome from our side here and thank you for being available a little bit earlier than usually. So therefore, good day, but also good morning, I guess, to some of you.

So let me start the presentation by walking you through the most important highlights of the year 2023, which really has been a year of transition in a very volatile life science industry where everybody has been impacted by several partially expected, partially unexpected developments.

So first of all, the preliminary results for the group and both divisions are well in line with the adjusted guidance that we shared with you in October. You will see the numbers in a minute. We have seen that the demand continued to gradually pick up. So for both divisions and therefore, of course, also for

Related Articles

Back to top button